Aicardi-Goutières syndrome: description of a late onset case
- PMID: 18754903
- DOI: 10.1111/j.1469-8749.2008.03033.x
Aicardi-Goutières syndrome: description of a late onset case
Abstract
Aicardi-Goutières syndrome (AGS) is a genetically determined encephalopathy usually inherited as an autosomal recessive trait. The syndrome can be caused by mutations in the AGS1 gene encoding the exonuclease TREX1, or in any of the AGS2, AGS3, or AGS4 genes that encode the three subunits of the human ribonuclease H2 (RNaseH2) complex. Typically, AGS has an early onset, usually manifesting by the age of 4 months. We describe a female infant in whom the onset of the neurological symptoms of AGS occurred after the age of 12 months, and her younger brother who was identified to be affected by AGS at the age of 8 months on the basis of the presence of non-neurological features alone. This paper is important in providing a detailed description of the late-onset presentation of AGS in patients with proven pathogenic mutations and highlights the occurrence of both chilblains and abnormal neuroimaging many months before the onset of neurological features. Our paper also considers the possible value of immunomodulatory therapy in AGS.
Similar articles
-
Expanding the phenotypic spectrum of lupus erythematosus in Aicardi-Goutières syndrome.Arthritis Rheum. 2010 May;62(5):1469-77. doi: 10.1002/art.27367. Arthritis Rheum. 2010. PMID: 20131292
-
Aicardi-Goutières syndrome (AGS).Eur J Paediatr Neurol. 2008 Sep;12(5):355-8. doi: 10.1016/j.ejpn.2007.11.010. Epub 2008 Mar 14. Eur J Paediatr Neurol. 2008. PMID: 18343173 Review.
-
Aicardi-Goutières syndrome: differential diagnosis and aetiopathogenesis.Funct Neurol. 2003 Apr-Jun;18(2):71-5. Funct Neurol. 2003. PMID: 12911136 Review.
-
Aicardi-Goutières syndrome: an update and results of interferon-alpha studies.Ann Neurol. 1998 Dec;44(6):900-7. doi: 10.1002/ana.410440608. Ann Neurol. 1998. PMID: 9851434
-
Aicardi-Goutières syndrome: an expanding phenotype.Neuropediatrics. 1998 Jun;29(3):163-7. doi: 10.1055/s-2007-973555. Neuropediatrics. 1998. PMID: 9706629
Cited by
-
Subacute Partially Reversible Leukoencephalopathy Expands the Aicardi-Goutières Syndrome Phenotype.Brain Sci. 2023 Aug 5;13(8):1169. doi: 10.3390/brainsci13081169. Brain Sci. 2023. PMID: 37626525 Free PMC article.
-
JAK Inhibition in Aicardi-Goutières Syndrome: a Monocentric Multidisciplinary Real-World Approach Study.J Clin Immunol. 2023 Aug;43(6):1436-1447. doi: 10.1007/s10875-023-01500-z. Epub 2023 May 12. J Clin Immunol. 2023. PMID: 37171742 Free PMC article.
-
Clinical spectrum and currently available treatment of type I interferonopathy Aicardi-Goutières syndrome.World J Pediatr. 2023 Jul;19(7):635-643. doi: 10.1007/s12519-022-00679-2. Epub 2023 Jan 17. World J Pediatr. 2023. PMID: 36650407 Free PMC article. Review.
-
Case Report: Generalised Panniculitis as a Post-COVID-19 Presentation in Aicardi-Goutières Syndrome Treated With Ruxolitinib.Front Pediatr. 2022 Apr 25;10:837568. doi: 10.3389/fped.2022.837568. eCollection 2022. Front Pediatr. 2022. PMID: 35547545 Free PMC article.
-
Relapsing-remitting clinical course expands the phenotype of Aicardi-Goutières syndrome.Ann Clin Transl Neurol. 2020 Feb;7(2):254-258. doi: 10.1002/acn3.50979. Epub 2020 Jan 10. Ann Clin Transl Neurol. 2020. PMID: 31920009 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous